Cyclerion Therapeutics Inc
CYCN1.690USD
-0.170-9.14%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
5.20MMarket Cap
LossP/E TTM
More Details of Cyclerion Therapeutics Inc Company
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Cyclerion Therapeutics Inc Info
Ticker SymbolCYCN
Company nameCyclerion Therapeutics Inc
IPO dateMar 18, 2019
CEODr. Regina M. Graul, Ph.D.
Number of employees1
Security typeOrdinary Share
Fiscal year-endMar 18
Address301 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02142
Phone16176217722
Websitehttps://www.cyclerion.com/
Ticker SymbolCYCN
IPO dateMar 18, 2019
CEODr. Regina M. Graul, Ph.D.
Company Executives of Cyclerion Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Other
65.68%
Shareholders
Shareholders
Proportion
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Other
65.68%
Shareholder Types
Shareholders
Proportion
Individual Investor
22.05%
Corporation
9.43%
Investment Advisor
5.69%
Investment Advisor/Hedge Fund
5.63%
Hedge Fund
0.08%
Research Firm
0.03%
Other
57.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
33
381.61K
11.43%
-552.00K
2025Q2
47
1.50M
44.80%
-242.81K
2025Q1
64
1.40M
44.62%
-170.60K
2024Q4
68
1.21M
44.74%
-507.00K
2024Q3
71
1.75M
64.88%
-8.65K
2024Q2
75
1.75M
64.62%
-27.65K
2024Q1
84
1.73M
66.48%
-9.21K
2023Q4
93
1.67M
68.18%
-15.51K
2023Q3
103
1.45M
60.44%
-312.49K
2023Q2
122
1.38M
57.36%
-283.95K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hecht (Peter M)
559.20K
16.76%
--
--
Apr 21, 2025
J. Wood Capital Advisors LLC
181.82K
5.45%
+181.82K
--
Apr 21, 2025
Tyndall Management, LLC
155.19K
4.65%
-9.59K
-5.82%
Jun 30, 2025
American Endowment Foundation
133.03K
3.99%
+133.03K
--
Dec 31, 2024
Invus Public Equities Advisors, LLC
116.16K
3.48%
--
--
Jun 30, 2025
Graul (Regina Margaret)
55.78K
1.67%
-44.52K
-44.39%
Apr 21, 2025
De Souza (Errol B)
50.00K
1.5%
--
--
Apr 21, 2025
Geode Capital Management, L.L.C.
32.73K
0.98%
+1.13K
+3.58%
Jun 30, 2025
Higgins (Michael J)
30.74K
0.92%
+1.65K
+5.67%
Apr 21, 2025
The Vanguard Group, Inc.
23.49K
0.7%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
Date
Type
Ratio
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
